Soligenix, Inc.
SNGX$12M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaPRINCETON14 employees
Drugs in Pipeline
6
Phase 3 Programs
3
Upcoming Catalysts
2
Next Catalyst
Jul 15, 2026
17wMarket Overview
Stock performance and key metrics
SNGX News
Catalyst Timeline
2 upcoming, 1 past
Drug Pipeline
SGX301 (synthetic hypericin)
Cutaneous T-Cell Lymphoma
Hypericin
Cutaneous T-Cell Lymphoma/Mycosis Fungoides
SGX942
Oral Mucositis
SGX201 (delayed release beclomethasone 17,21-dipropionate)
Enteritis
Dusquetide
Behçet Disease
Mechlorethamine Topical Gel
Cutaneous T-Cell Lymphoma/Mycosis Fungoides
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SGX301 (synthetic hypericin) | Phase 3 | Cutaneous T-Cell Lymphoma | - | - |
Hypericin | Phase 3 | Cutaneous T-Cell Lymphoma/Mycosis Fungoides | - | - |
SGX942 | Phase 3 | Oral Mucositis | - | - |
SGX201 (delayed release beclomethasone 17,21-dipropionate) | Phase 2 | Enteritis | - | - |
Dusquetide | Phase 2 | Behçet Disease | - | - |
Mechlorethamine Topical Gel | Phase 2 | Cutaneous T-Cell Lymphoma/Mycosis Fungoides | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply